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Systematic reviewa b s t r a c t
Background: The diagnosis of Takotsubo syndrome is made based on clinical presentation, ECG, biomar-
ker, imaging and coronary angiography. There is a lack of diagnostic biomarkers that can discriminate
patients with Takotsubo syndrome from those with acute myocardial infarction (AMI) and provide clin-
ical monitoring and prognostic information in the long-term.
Methods: A literature search of published Takotsubo syndrome biomarkers from PubMed was performed.
All studies that included numerical biomarker data on Takotsubo syndrome was included. Exclusion cri-
teria was any study without an AMI cohort for comparison in the acute phase biomarkers or due to the
absence of numerical values. The results were tabulated in table form with results expressed as either
mean ± SD or median (interquartile range).
Results: The literature search produced 14 relevant studies that met search criteria. The results showed;
high sensitivity Troponin I (3.21 ± 4.4 vs 34.4 ± 37 ng/ml), BNP [972 (578.5–1671.0) pg/L vs 358 (50.5–
688.0) pg/L in NSTEMI and vs 381 (106.0–934.0) pg/L in STEMI] and BNP/Troponin I ratio [642 (331.8–
1226.5) vs 184.5 (50.5–372.3) pg/ug in NSTEMI and 7.5 (2.0–29.6) pg/ug in STEMI] patients.
Discussion: This study is limited by many studies being retrospective cohort studies. This data shows that
acutely troponin is raised in Takotsubo syndrome but not enough to be discriminating from AMI. BNP
level is significantly raised in Takotsubo syndrome compared to AMI.
Conclusion: Current specificity of acute and chronic biomarkers for Takotsubo syndrome is lacking and
further work is needed to address the gap in knowledge.
 2021 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
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Takotsubo syndrome (stress induced cardiomyopathy), is a
recently described acute cardiac presentation that mimics an acute
myocardial infarction (AMI). The current diagnostic criteria for
Takotsubo typically focus on AMI-like symptoms and ECG changes,
cardiac biomarker release, imaging evidence of left ventricular dys-
function – often of transient nature - and intense myocardial
oedema, in the absence of causative culprit plaque on coronary
angiography [1,2].
Patients with Takotsubo syndrome usually present with chest
pain and ECG changes which are unable to reliably differentiate
them from patients with AMI. For those presenting with
ST-elevation the diagnosis is rapidly established with invasive
coronary angiography. A diagnostic biomarker, no matter how
specific is unlikely to be of additional utility or to replace the need
for coronary angiography in this group of patients. The majority of
Takotsubo patients present with non-ST elevation and undergo in-
hospital stay and pre-coronary angiography treatment typical for
AMI so they are commonly prescribed antiplatelet and anti-
coagulant therapy, for which there is no evidence of clinical benefit
[3]. In such patients a diagnostic biomarker could be utilised in
conjunction with non-invasive coronary angiography and the
already described differentiating features of the ECG evolution over
the initial 3 days, specifically deep and widespread T wave inver-
sion and increased QTc interval [4]. In addition, cardiac magnetic
resonance imaging will exclude fibrosis (shown as late gadolinium
enhancement) and confirm the presence of myocardial oedema
which usually confirms the diagnosis [5].
Whilst a specific diagnostic biomarker for Takotsubo syndrome
does not exist and may be difficult to envisage before addressing
the causative pathophysiology of the disease, matters may be dif-
ferent regarding the clinical utility of a biomarker used in recovery,
convalescence, or long-term follow-up. From a prognostic and
therapeutic perspective, biomarker monitoring may help select
the patient population who may benefit from medical therapies
(such as ACE-inhibition(1) suggested by registry data) or guide
the duration of such treatments, given the dynamic nature of the
condition (for example first 3–6 months versus life-long). In addi-
tion, a pure understanding of the biomarker profile in Takotsubo
syndrome may allow a better understanding of the pathophysiol-
ogy of the condition which will aid in the development of better
treatments in the future.
Here, we review the literature available on biomarkers in
Takotsubo syndrome. From an acute perspective we focused on a
comparison with patients with AMI to identify clinically relevant
differences that may guide clinicians in early detection, investiga-
tion and management of acute Takotsubo syndrome. From a
chronic perspective we focus on biomarkers with a role in disease
monitoring and risk stratification, we visit several pathophysiolog-
ical pathways that may be important in understanding the mech-
anism behind Takotsubo syndrome.2
2. Methods
2.1. Study design
The study was designed as a systematic review (see Table 3, 4
and 5). A literature search of published Takotsubo syndrome
biomarkers (1990 to 2021, English language only) from PubMed
Library was performed. Search terms included: (biomarkers in
Takotsubo cardiomyopathy), (biomarkers in Takotsubo syndrome),
(markers of mortality in Takotsubo cardiomyopathy), (biomarkers
in stress induced cardiomyopathy), (markers of death in Takotsubo
cardiomyopathy), (markers of mortality in stress induced car-
diomyopathy), (markers of death in stress induced cardiomyopa-
thy). Relevant mean/median values, standard deviations, or
standard errors of the mean and/or range were noted, if available,
as well as timing of sampling relative to admission.
2.2. Eligibility criteria
We included adult patients (18 years and older) with a diagno-
sis of Takotsubo syndrome based either on the Mayo clinic criteria
or the European society of cardiology criteria. All studies included
had performed repeat imaging after several months to confirm the
diagnosis of Takotsubo syndrome.
2.3. Exclusion criteria
We excluded any studies which did not include an AMI com-
parator group when assessing acute biomarkers. We excluded
studies which did not have any control group for chronic biomark-
ers. In addition, we excluded case reports of biomarkers in Takot-
subo syndrome. We also excluded studies which did not present
biomarker data in numerical values with a mean ± SD or median
(interquartile range).
2.4. Data items and data collection
We collected data on the author of the study, the year of the
study, the number of patients included in the study, the unit of
measurement of the biomarker in question, timing of sample from
admission, the time from symptom onset to admission, the value of
the biomarker in Takotsubo syndrome, the value of the biomarker
in AMI patients, the p-value and the normal reference range if
available.3. Results
3.1. Literature selection
The initial search strategy produced 675 articles. After screen-
ing the article abstract the number reduced to 43 articles. A further
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absence of either an AMI cohort for comparison in the acute phase
biomarkers or due to the absence of numerical values (results pre-
sented only in graphical format). Fourteen papers were included in
the final data analysis (Fig. 1). All these studies used the Mayo
clinic criteria to diagnose patients with Takotsubo syndrome.
3.2. Biomarkers in acute Takotsubo syndrome
We identified 13 papers that reported one or several acute
biomarkers in patients with Takotsubo syndrome compared to
patients with AMI, reporting on a total of 1194 patients.
Table 1 presents 27 biomarkers investigated during the acute
phase. These were subdivided into 5 categories:
3.2.1. Markers of cardiac injury/stretch
Table 1a shows the classical markers of cardiac injury - Tro-
ponin I, Troponin T (TnT), Creatine Phosphokinase (CK), Creatine
Phosphokinase MB fraction (CKMB), Myoglobin - and stretch –
BNP - as well as various ratios between them: BNP/Troponin I ratio,
hs-TnT/CKMB, BNP/TnT and BNP/CKMB.
The peak Troponin I ranged between 1.6 (0.7–3.1) ng/mL, 7.6 n
g/dl ± 18, 2.1 ng/ml (0.7–4.0) in TTC compared to 51.4 (27.6–80.1)
ng/mL, 19 ng/ml (7.4–52.9), 102.2 ng/dl ± 110.3 in STEMI patients.
The brain natriuretic peptide (BNP) level at admission in patientsFig. 1. Systematic literature re
3
with TTC is 972 (578.5–1671.0) pg/L, 456.5 pg/ml [120.25–734.5]
compared to 358 (50.5–688.0) pg/L in NSTEMI, 381 (106.0–934.0)
pg/L in STEMI. The BNP/TnI ratio is 642 (331.8–1226.5) pg/ug in
Takotsubo cardiomyopathy and 184.5 (50.5–372.3) pg/ug in
NSTEMI and 7.5 (2.0–29.6) pg/ug in STEMI patients.3.2.2. Markers of the Immune/Inflammatory response
Table 1b elaborates the pro- and anti-inflammatory cytokines
produced by activation of the innate immune system such as
phagocytic leucocytes or activated immune tissue cells such as
macrophages and dendritic cells: the interleukins family (IL-1b,
IL-6, IFN-c, TNF-a, IL-2, IL-4, IL-10), Suppression-of-
tumorigenicity 2 and Soluble Thrombomodulin.
The IL-6 level is 112.37 pg/ml ± 17.48 at 0 h and 7.35 pg/ml ± 7.
10 at 2 h in TTC compared to 25.42 pg/ml ± 27.71 at 0 h and 19.
6 pg/ml ± 23.05 at 2 h in AMI patients, Pirzer et al showed that
IL-6 levels at admission in TTC patients is 2.1 pg/ml ± 2.6 compared
to 5.2 pg/ml +/- 5.0 in patients with AMI. The Interferon (IFN)-c
level is 0.92 pg/ml ± 0.64 at 0 h and 1.45 pg/ml ± 1.41 at 2 h in
TTC compared to 0.32 pg/ml ± 0.47 at 0 h and 0.41 pg/ml ± 0.68
at 2 h in AMI patients. The Tissue necrosis factor (TNF)-a level is
5.02 pg/ml ± 4.7 at 0 h and 4.44 pg/ml ± 2.88 at 2 h in TTC com-
pared to 2.33 pg/ml ± 1.98 at 0 h and 3.09 pg/ml ± 3.90 at 2 h in
AMI patientsview search flow diagram.
Table 1
Biomarkers in acute Takotsubo syndrome.





















Santoro et al. [12] NA 2018 64 ng/ml TnI at admission 3.21 ± 4.4b 34.4 ± 37 (ACS)e 0.01 <0.5
Nascimento et al. [35] NA 2012 154 ng/dl TnI at 8–12 h 7.6 ± 18 102.2 +/- 110.3 (STEMI) <0.001 NA
Budnik et al. [11] TTS-8 h
AMI-5 h
2015 132 ng/ml TnI at 12 h 2.1 (0.7–4.0) 19 (7.4–52.9) (STEMI) < 0.001 NA
Troponin T
Randhawa et al. [9] NA 2014 155 ng/ml Troponin T at
admission
0.38 (0.16–0.65) 0.52 (0.19–1.45) (AMI)f 0.0092 NA
Frohlich et al. [10] TTS-7.5 h
STEMI-6 h
NSTEMI-10 h
2012 121 ug/l Troponin T at
admission












Frohlich et al. [10] TTS-7.5 h
STEMI-6 h
NSTEMI-10 h







Creatine Phosphokinase MB fraction





Randhawa et al. [9] NA 2014 155 ng/ml CPK-MB at
admission
10.5 (5.8–14.9) 25.0 (13.8–62.7) (AMI) <0.0001 NA
Frohlich et al. [10] TTS-7.5 h
STEMI-6 h
NSTEMI-10 h





Budnik et al. [11] TTS-8 h
AMI-5 h




Doyen et al. [6] NA 2014 152 UI/L Myoglobin at
peakb







Frohlich et al. [10] TTS-7.5 h
STEMI-6 h
NSTEMI-10 h
2012 121 ug/l Myoglobin at
admission















Randhawa et al. [9] NA 2014 155 pg/ml BNP at admission 456.5 (120.25–734.5) 97 (45.5–248.5) <0.0001 NA
Frohlich et al. [10] TTS-7.5 h
STEMI-6 h
NSTEMI-10 h
2012 121 ng/L NT-pro-BNPj at
admission







Budnik et al. [11] TTS-8 h
AMI-5 h
2015 132 ng/ml NT-pro-BNP at
12 h




Doyen et al. [6] NA 2014 152 BNP at admission
Tn I-peakb






Budnik et al. [11] TTS-8 h
AMI-5 h
2015 132 NT-pro-BNP and
Tn-I at 12 h
2235.2 (1086.2–9480.8) 81.6 (47.9–383.3)
(STEMI)
< 0.001 NA
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Table 1 (continued)















Pirlet et al. [36] TTS-20 h
NSTEMI-7.7 h
STEMI-3.5 h




















Randhawa et al. [9] NA 2014 155 BNP and TnT at
admission




Randhawa et al. [9] NA 2014 155 BNP and CKMB at
admission
28.4 (13.7–94.8) 3.6 (1.1–10.0) (AMI) <0.001 NA

















Santoro et al. [12] NA 2018 64 pg/ml IL-1bl at 0 h









Santoro et al. [12] NA 2018 64 pg/ml IL-6m at 0 h










Pirzer et al. [14] TTS-6 h
AMI-6 h
2012 32 pg/ml IL-6 at admission 2.1 ± 2.6 5.2 ± 5.0 (ACS) NA
Interferon-c
Santoro et al. [12] NA 2018 64 pg/ml IFN-cn at 0 h











Santoro et al. [12] NA 2018 64 pg/ml TNF-ao at 0 h
TNF-a at 2 h
5.0 ± 4.7
4.44 ± 2.88







Santoro et al. [12] NA 2018 64 pg/ml IL-2p at 0 h
IL-2 at 2 h
2.0 ± 1.5
4.6 ± 5.3
0.5 ± 0.1 (ACS)





Santoro et al. [12] NA 2018 64 pg/ml IL-4q at 0 h
IL-4 at 2 h
1.5 ± 1.0
1.6 ± 0.7
0.8 ± 1.1 (ACS)





Santoro et al. [12] NA 2018 64 pg/ml IL-10r at 0 h
IL-10 at 2 h
3.3 ± 3.8
2.8 ± 3.5
1.6 ± 2.2 (ACS)





Hojagergaard et al. [23] NA 2019 60 ng/ml Suppression-of-
tumorigenicity 2 at
admission




Hojagergaard et al. [23] NA 2019 60 ng/ml Soluble Thrombomodulin
at admission
7.9 (5.9–9.6) 6.4 (5.5–7.8)
(STEMI)
0.04 NA


















Stiermaier et al. [37] NA 2011 44 ng/l Growth differentiation
factor-15 at admission




Santoro et al. [12] NA 2018 64 pg/ml EGFs at 0 h
EGF at 2 h
84.8 ± 42.9
36.3 ± 18.5
10.7 ± 11.2 (ACS)
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NA 2019 60 pmol/l Copeptin at
admission







2020 29 ng/ml Copeptin at
admission











41 ± 10 (healthy
controls)
256 ± 208 (AMI) < 0.0001
0.005
NA



















































0.78 (0.66–0.90)3 0.64 (0.50–0.79)4 <0.0013
0.064
NA
TnI- Troponin I a) Value represented as median [interquartile range].
Levels measured every 6 h, peak defined as maximal level before decrease in biomarker b) Value represented as mean ± standard deviation.
NSTEMI – Non-ST elevation myocardial infarction c) Area Under Curve – Takotsubo Syndrome versus Healthy Controls.
STEMI – ST elevation myocardial infarction d) Area Under Curve – Takotsubo Syndrome versus STEMI.
ACS – Acute Coronary Syndrome TTS = takostubo syndrome, AMI = acute myocardial infarction, NA = not available.
AMI – Acute Myocardial Infarction.
CPK-Creatinine phosphokinase.
CPK-MB-Creatinine phosphokinase MB isoform.
BNP-Brain natriuretic peptide.
NT-pro-BNP- N terminal - pro-Brain natriuretic peptide.
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differentiation)
Table 1c shows the activation of Growth differentiation factor-
15 and endothelial growth factor (EGF) – as signalling molecules
promoting repair and differentiation.
The Growth differentiation factor 15 (GDF-15) levels at admission
were between 3047 ng/l (2256–7572) ng/l in TTC patients compared
to 1527 ng/l (1152–2677) in STEMI patients. The Endothelial
growth factor (EGF) level is 84.77 pg/ml ± 42.91 at 0 h and
36.32 pg/ml ± 18.46 at 2 h in TTC compared to 10.65 pg/ml ±
11.22 at 0 h and 18.49 pg/ml ± 25.33 at 2 h in AMI patients.3.2.4. Markers of vascular stress (haemodynamic, ischemic, metabolic)
Table 1d shows the information derived from the contribution
of vascular responses in Takotsubo syndrome, the most studied
are Copeptin (peptide derived from the C-terminus of
pre-pro-hormone arginine vasopressin) and Syndecan-1 (a trans-
membrane proteoglycan) as biomarkers of vascular stress.
The copeptin level is 10.4 pmol/l (7.6–39) and 0.49 ng/ml
(0.45–1.21) at admission in TTC patients compared to 92.3
pmol/l (13–197) and 1.55 ng/ml (1.34–1.65) in STEMI patients.6
3.2.5. Circulating micro-RNA (miRNA) profiling of dysregulated
pathways
Table 1e details families of circulating non-coding RNA mole-
cules which function as post-transcriptional regulators of gene
expression most recently recognised as biological regulators
(miR-16, miR-26a, miR-133a, miR-1).
The level of miR-16 is 0.76 (0.64 – 0.88) in Takotsubo syndrome
and 0.78 (0.66 – 0.89) in AMI patients. The level of miR-26a is 0.73
(0.59 – 0.86) in Takotsubo syndrome and 0.70 (0.56 –0.84) in AMI.3.3. Biomarkers in convalescent and chronic post-Takotsubo syndrome
Stages
We identified 1 study that explored biomarkers in Takotsubo
syndrome patients after the acute presentation. These were Tro-
ponin I, IL-6, IL-8, BNP studied in a total of 106 patients which
are shown in Table 2.
The hs TnI level in convalescent Takotsubo syndrome was
6.47 ± 0.6 (reference range < 5). The BNP level is 77.9 ± 45 in Takot-
subo syndrome and 32.7 ± 4.6 in healthy controls. The IL-6 level is
18.3 ± 5.17 in Takotsubo syndrome and 6.5 ± 5.838 in healthy
Table 2
Biomarkers in Convalescent and Chronic Takotsubo syndrome Stages.















Scally et al. [2] 2019 106 (ng/L) hsTroponin Ia at
5 months
6.47 ± 0.6* NA NA <5 (detectable
limit)
Interleukin-6
Scally et al. [2] 2019 106 (pg/ml) IL-6b at 5 months 18.3 ± 5.17 6.5 ± 5.83 0.008 NA
Interleukin-8
Scally et al. [2] 2019 106 (pg/ml) IL-8c at 5 months 61.9 ± 10.28 21.7 ± 10.86 0.009 NA
BNPd
Scally et al. [2] 2019 106 (pg/ml) BNP at 5 months 77.9 ± 45
(Mean ± SD)
32.7 ± 4.6 0.003 NA
a hsTroponin I- high sensitivity Troponin I.
b IL-6- Interleukin-6.
c IL-8- Interleukin-8.
d BNP- Brain natriuretic peptide.
* Value represented as mean ± standard deviation.
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Doyen et al. [6] * * * * * * * * 8
Randhawa et al. [9] * * * * * * * * 8
Frohlich et al. [10] * * * * * * * * 8
Budnik et al. [11] * * * * * * * * 8
Santoro et al. [12] * * * * * * * * 8
Pirzer et al. [14] * * * * * * * * 8
Nguyen et al. [19] * * * * * * * * 8
Jaguszewski et al. [22] * * * * * * * * 8
Hojagergaard et al. [23] * * * * * * * * 8
Budnik et al. [24] * * * * * * * * 8
Pirlet et al. [36] * * * * * * * * 8
Stiermaier et al. [37] * * * * * * * * 8
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21.7 ± 10.86 in healthy controls.4. Discussion
We collated currently available biomarker data from patients
with Takotsubo syndrome as a comparator with AMI. A Takotsubo
syndrome-specific biomarker does not exist and such a biomarker
would require an unprecedented degree of accuracy (implying
rapid or pre-existent release of such a protein), ultra-rapid testing
availability in order to obviate coronary angiography on those pre-
senting with ST-elevation. It is important therefore to re-appraise if
for diagnostic purposes there is particular value in any such exist-
ing biomarker or a combination thereof and at what stage in the
diagnostic pathway it could be clinically helpful (for example 12
or 24 h, such as is the case with AMI) – this being relevant to those
presenting without ST-elevation on ECG. In the absence of high
specificity, any clinical biomarker must continue to be utilised in
conjunction with other clinical investigations (ECG, and Cardiac
imaging) for an accurate diagnosis. A biomarker in Takotsubo syn-
drome may help select patients that could be assessed non-7
invasively by computed tomography coronary angiography pro-
vided they are stable and pain free [5]. It also may help in
follow-up, identification of candidates for long term therapies
and those at increased risk.4.1. Acute biomarkers
Cardiac markers of injury and stretch collectively showed that
Troponin isoforms, CK or CK-MB are lower in Takotsubo patients
compared with STEMI and of comparable or lower levels than
patients with NSTEMI [6]. It would be unjustifiable to delay pri-
mary percutaneous diagnostic and interventional pursuits in any-
one presenting with ST-elevation ECG, the case is however
different for the NSTEMI presenters. Both point of care and 12-
hour troponin or 12–24-hour CK/CK-MB assays are usually avail-
able before further invasive investigations are instigated, although
antiplatelet and anticoagulation therapy is commenced in all.
However, NSTEMI’s typically have lesser rise in cardiac injury/
necrosis biomarkers, thus almost overlapping with those seen in
Takotsubo, therefore they do not accurately differentiate Takot-
subo syndrome from AMI [7]. Unlike in AMI (where the acute
Table 4
PRISMA 2020 checklist.
Line 1Section and Topic Item
#
Checklist item Location where
item is reported
TITLE
Title 1 Identify the report as a systematic review. Line 1
ABSTRACT
Abstract 2 See the PRISMA 2020 for Abstracts checklist. See Abstract
Checklist
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of existing knowledge. Line 66–95
Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. Line 97–102
METHODS
Eligibility criteria 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the
syntheses.
Line 124–134
Information sources 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or
consulted to identify studies. Specify the date when each source was last searched or consulted.
Line 114–123
Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits
used.
Line 115–121
Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including
how many reviewers screened each record and each report retrieved, whether they worked
independently, and if applicable, details of automation tools used in the process.
135–140
Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from
each report, whether they worked independently, any processes for obtaining or confirming data from
study investigators, and if applicable, details of automation tools used in the process.
Line 135–140
Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible
with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if
not, the methods used to decide which results to collect.
Line 135–140
10b List and define all other variables for which data were sought (e.g. participant and intervention
characteristics, funding sources). Describe any assumptions made about any missing or unclear
information.
Line 135–140
Study risk of bias
assessment
11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used,
how many reviewers assessed each study and whether they worked independently, and if applicable,
details of automation tools used in the process.
Table 3
Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or
presentation of results.
Line 121–123
Synthesis methods 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the
study intervention characteristics and comparing against the planned groups for each synthesis (item
#5)).
Line 124–140
13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of
missing summary statistics, or data conversions.
NA
13c Describe any methods used to tabulate or visually display results of individual studies and syntheses. NA
13d Describe any methods used to synthesize results and provide a rationale for the choice(s). Ifmeta-analysis
was performed, describe the model(s), method(s) to identify the presence and extent of statistical
heterogeneity, and software package(s) used.
NA
13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g.
subgroup analysis, meta-regression).
NA
13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. NA
Reporting bias assessment 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from
reporting biases).
Table 3
Certainty assessment 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. NA
RESULTS
Study selection 16a Describe the results of the search and selection process, from the number of records identified in the
search to the number of studies included in the review, ideally using a flow diagram.
Line 156–223
16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why
they were excluded.
NA
Study characteristics 17 Cite each included study and present its characteristics. Table 1-2
Risk of bias in studies 18 Present assessments of risk of bias for each included study. Table 3
Results of individual
studies
19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and
(b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or
plots.
Table 1-2
Results of syntheses 20a For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. NA
20b Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the
summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical
heterogeneity. If comparing groups, describe the direction of the effect.
NA
20c Present results of all investigations of possible causes of heterogeneity among study results. NA
20d Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. NA
Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis
assessed.
NA
Certainty of evidence 22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. NA
DISCUSSION
Discussion 23a Provide a general interpretation of the results in the context of other evidence. Line 228–348
23b Discuss any limitations of the evidence included in the review. Line 349–352
23c Discuss any limitations of the review processes used. Line 352–354
23d Discuss implications of the results for practice, policy, and future research. Line 360–370
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#
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OTHER INFORMATION
Registration and protocol 24a Provide registration information for the review, including register name and registration number, or state
that the review was not registered.
NA
24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. NA
24c Describe and explain any amendments to information provided at registration or in the protocol. NA
Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or
sponsors in the review.
NA
Competing interests 26 Declare any competing interests of review authors. Declaration forms
Availability of data, code
and other materials
27 Report which of the following are publicly available and where they can be found: template data
collection forms; data extracted from included studies; data used for all analyses; analytic code; any other
materials used in the review.
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infarct size and thus prognostically important), the amount of Tro-
ponin release in the acute Takotsubo stage is not known to have
long-term prognostic implications.
An interesting and consistent observation has been the rather
high BNP levels in Takotsubo syndrome compared to patients with
AMI. A likely explanation is the acute left ventricular ballooning9
and raised filling pressures in a left ventricular cavity which has
suddenly lost its contractile function. BNP is also an acute phase
reactant and it is also possible that this elevation reflects its anti-
inflammatory contribution to the syndrome [8]. BNP tests are
widely available, also as point of care assays [9,10]. Testing of
BNP alone however does not have enough specificity to reliably dif-
ferentiate Takotsubo syndrome from AMI, particularly in larger
infarcts, where BNP can also be very high.
Given the opposite patterns of change in Takotsubo syndrome
(lower troponin, higher BNP) compared to AMI, the BNP/troponin
ratio appears significantly elevated in patients with Takotsubo syn-
drome and has a higher sensitivity and specificity for discriminat-
ing Takotsubo syndrome from AMI. Doyen et al showed that a ratio
greater than 159 had a 95.2% sensitivity and a 97.9% specificity for
discriminating patients with Takotsubo syndrome from AMI [6,11].
Whilst requiring larger studies to validate it for routine use, the
benefit of this acute, diagnostic biomarker ratio is that both are
already in clinical use.
We have previously demonstrated that Takotsubo syndrome is
characterised by intense myocardial and systemic inflammation
[2]. Santoro and colleagues evaluated inflammatory markers as
diagnostic tools in patients with Takotsubo syndrome. IL-2, IL-4,
IL-10, IFN-c and TNF-a at admission were shown to be significantly
higher in patients with acute Takotsubo syndrome compared to
patients with AMI, conversely, IL-6 was much higher in AMI
patients [12]. This is probably because of the necrotic myocardium
in AMI which attracts an immediate and large pool of neutrophil
infiltration, which is mainly responsible for the IL-6 rise, whereas
necrosis is not characteristically found in Takotsubo myocardium
[13]. Consequently, elevated IL-6 levels persist beyond acute pre-
sentation [12] in to the subacute phase of AMI [14]. However,
the elevated IL-2 and IL-4 levels in Takotsubo syndrome point
towards activation of circulating CD4 and CD8 T cells as these
are the primary source of these interleukins. The levels of IL-10
which is an anti-inflammatory cytokine rise due to the abundance
of macrophages surrounding the myocardial tissue subjected to
very high wall stress in Takotsubo syndrome. Thus, there is likely
to be more IL-10 released in Takotsubo syndrome compared to
AMI patients due to the pro-inflammatory nature of Takotsubo
syndrome [12] which needs to be counteracted as part of the
mechanism of homeostasis. In addition, IL-10 likely prevents car-
diomyocyte apoptosis via TNF-a, accounting for the functional
recovery in patients with Takotsubo syndrome [15]. TNF-a and
IFN-c (both pro-inflammatory cytokines) are significantly elevated
in Takotsubo syndrome compared to AMI, also likely reflecting the
inflammatory substrate of Takotsubo syndrome. TNF-a has direct
cardiotoxic effects with reductions in cardiac inotropy; once levels
of TNF-a fall this effect is immediately reversible without any
residual left ventricular impairment in rats exposed to TNF-a infu-
sions [16]. The levels of IFN-c are elevated in both hypertensive
H. Khan, D. Gamble, A. Mezincescu et al. IJC Heart & Vasculature 34 (2021) 100795and aged models of the rat heart demonstrating that any inflam-
matory process can lead to an accumulation of CD4 and CD8 cells
which are a major source of IFN-c [17]. This supports the strong
inflammatory mechanism/circuit for Takotsubo syndrome as there
is a preponderance for significantly elevated proinflammatory
cytokines compared to AMI patients.
Beyond acute presentation, some of the chemokines and inter-
leukins appear to remain elevated, suggesting a low-grade, chronic
inflammatory state after Takotsubo syndrome [2], which we
believe contributes to the chronic heart failure phenotype [18].
Takotsubo is also recognised to affect the vascular stress
responses. Thus, co-peptin has showed some promise in patients
with Takotsubo syndrome as its levels are normal or marginally
elevated compared to more substantial elevations in patients with
AMI. Other markers of vascular stress such as glycocalyx levels are
significantly elevated in Takotsubo compared to healthy controls
reflecting endothelial injury that may lead to increased vascular
permeability (ultimately responsible for the intense myocardial
oedema seen in patients with Takotsubo syndrome) [19]. This also
supports the theory of nitrosative stress in Takotsubo syndrome
whereby excessive catecholamine stimulation of the myocardium
leads to the development of free radicals which cause direct myo-
cyte inflammation which leads to shedding of the glycocalyx and
intense myocardial oedema [20]. The levels of syndecan-1 however
are much higher in patients with AMI this likely reflects the fact
that the level of injury to the vascular architecture in AMI is several
folds greater than that which may occur in Takotsubo syndrome.
Syndecan-1 likely reflects the degree of overall vascular injury in
MI (as it is not correlated with infarct size) and is involved in the
vascular repair process [21].
Takotsubo syndrome patients have elevated endothelin levels
suggesting possible microvascular vasoconstriction in response to
endothelial dysfunction [22]. This contrasts with the vasoconstrict-
ing hormone co-peptin (released centrally from the posterior pitu-
itary gland) which is normal or only marginally elevated in
Takotsubo syndrome, compared to more substantial elevations in
patients with AMI. This suggests the arginine-vasopressin system
is not implicated in Takotsubo syndrome [23–25] or it may be
supressed or even exhausted. The differences between these two
vasoconstricting peptides may be explained by the local upregula-
tion and secretion of endothelin by local factors such as stretch,
hypoxia, free radicals and cytokines whereas co-peptin is released
centrally. IL-6 is implicated in the production of vasopressin which
could explain the higher level of co-peptin in AMI compared to the
lower levels seen in Takotsubo syndrome as the levels of IL-6 are
much lower in Takotsubo syndrome, as discussed already [26,27].
Patients with Takotsubo syndrome have altered microRNA sig-
nalling compared to STEMI patients and normal controls. There
was upregulation of miRNA 16 and 26a in Takotsubo syndrome,
both of which are upregulated in the brains of patients with
depression and anxiety [28,29]. This supports the concept of a
Brain-Heart axis which may underpin at least part of the pathogen-
esis of patients with Takotsubo syndrome and account for the anx-
iety/depression co-morbidities associated with the condition. The
levels of miRNA 1 and 133 which exist in a cluster with each other
in the myocardium are upregulated in patients with AMI compared
Takotsubo syndrome likely reflecting their role as a marker of
myocardial injury and necrosis [30].
4.2. Chronic biomarkers
After the acute presentation, in the chronic Takotsubo phase,
biomarkers that can provide prognostic information or allow clin-
ical monitoring in the aftermath of Takotsubo syndrome are
needed to target emerging therapies and design appropriate
surveillance strategies. Several biomarkers have emerged as10chronic biomarkers candidates. Scally et al showed that levels of
TnI, BNP, IL-6 and IL-8 remain modestly elevated at follow-up in
patients with Takotsubo syndrome [2]. BNP was also noticed to
be elevated at follow-up by Nguyen et al. [8]. This suggests that
the abnormalities in patients with Takotsubo syndrome persist
for many months after the acute diagnosis. Detectable levels of tro-
ponin and elevated levels of BNP are associated with poorer prog-
nosis in patients with cardiac disease [31,32]. There is a lack of data
on chronic (prognostic) biomarkers and their implication in Takot-
subo syndrome.
4.3. Limitations
One of the limitations of this systematic review is the large
numbers of studies which are retrospective in nature. This
increases the likelihood of selection bias and information bias in
these studies. This systematic review was performed in as thor-
ough a manner as possible however it is possible a very small num-
ber of studies could have been missed by our search strategy.
There has been a rise in the incidence of Takotsubo syndrome of
about 4–5-fold during the COVID pandemic [33]. In addition, case-
series have shown a significant mortality rate in patients with
Takotsubo syndrome and concomitant COVID-19 [34]. This rein-
forces the urgency for a renewed focus on research in this serious
cardiac condition
5. Conclusion
Takotsubo syndrome is a serious cardiac condition with an
increased incidence in the last decade due to better diagnostic
awareness and focused research. There is a diagnostic role for acute
biomarkers as a component of the comprehensive criteria for the
diagnosis of Takotsubo syndrome, which remains a diagnosis of
exclusion. A Takotsubo-specific acute diagnostic biomarker has
not yet been described. Biomarkers do help further our under-
standing of the pathophysiology of Takotsubo syndrome and sup-
port the very strong inflammatory substrate to the disease
process. There may be a prognostic role for biomarkers in selecting
patients who are at higher risk for more aggressive medical ther-
apy in the long-term but there remains a large knowledge gap in
this area. There is a need for further biomarker research to address
such questions which remain unanswered.
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Appendix A. Abbreviations
AMI = Acute Myocardial Infarction
TTS = Takotsubo syndrome
NSTEMI = non-ST-elevation myocardial infarction
STEMI = ST-elevation myocardial infarction
BNP = brain natriuretic peptide
NT-proBNPN-terminal pro B-type natriuretic peptide
GDF-15 = Growth differentiation factor-15
CPK = Creatine Phosphokinase
ACE = Angiotensin converting enzyme inhibitors
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TNF = Tissue necrosis factor
IFN = Interferon
EGF = Endothelial growth factor
miRNA = Micro Ribonucleic acid
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